Summary

Eligibility
for people ages 60 years and up (full criteria)
Location
at UCLA
Dates
study started
completion around
Principal Investigator
by Pradeep S. Prasad, MD, MBA (ucla)
Headshot of Pradeep S. Prasad
Pradeep S. Prasad

Description

Summary

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Official Title

A Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Keywords

Geographic Atrophy, Macular Degeneration, Atrophy, Prednisone, Triamcinolone, JNJ-81201887

Eligibility

Locations

Lead Scientist at University of California Health

  • Pradeep S. Prasad, MD, MBA (ucla)
    HS Associate Clinical Professor, Ophthalmology, Medicine. Authored (or co-authored) 24 research publications

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Janssen Research & Development, LLC
ID
NCT05811351
Phase
Phase 2 research study
Study Type
Interventional
Participants
About 305 people participating
Last Updated